Kura Oncology to Present Darlifarnib Plus Cabozantinib Data in Patients with Clear Cell Renal Cell Carcinoma Previously Treated with Cabozantinib at IKCS Europe 2026

Rhea-AI Summary

Kura Oncology (Nasdaq: KURA) will present updated Phase 1 FIT-001 data showing that darlifarnib combined with cabozantinib produced encouraging clinical activity and a manageable safety profile in advanced clear cell renal cell carcinoma patients previously treated with cabozantinib.

The presentation is scheduled for April 17, 2026 at IKCS Europe 2026; a virtual investor webcast and replay will follow at 7:30 a.m. PT / 10:30 a.m. ET.

Argus Apr 9 session

+0.68% close to close Open Argus

Details

News Market Reaction – KURA

In the Apr 9 session, KURA gained 0.68%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights updated Phase 1 data from the FIT-001 trial of darlifarnib (KO-2806) pl...

Analysis

This announcement highlights updated Phase 1 data from the FIT-001 trial of darlifarnib (KO-2806) plus cabozantinib in clear cell renal cell carcinoma, to be presented at IKCS Europe 2026 and discussed on an investor call on April 17, 2026. It builds on encouraging activity and safety reported at ESMO 2025. Investors may watch for consistency of response, durability, and safety in patients previously treated with cabozantinib, as well as clarity on next trial steps and combination strategies.

Key Figures

Clinical trial ID: NCT 06026410 Conference year: 2025 Conference year: 2026 +4 more

Clinical trial ID

NCT 06026410

FIT-001 trial identifier in RCC

Conference year

2025

Prior FIT-001 data presented at ESMO 2025

Conference year

2026

Updated FIT-001 data at IKCS Europe 2026

Abstract session

7

IKCS Europe 2026 abstract session number

Presentation date

April 17, 2026

IKCS Europe 2026 presentation timing

Presentation time

3:30 p.m. – 4:30 p.m. CEST

IKCS Europe 2026 session window

Investor call time

7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST

Virtual investor event on April 17, 2026

Historical Context

5 past events · Latest: Mar 06

5 events

1. Mar 06

   Inducement option grants

   24h Move

   +5.3%

   Reported new employee inducement stock options totaling 44,700 shares.

2. Mar 05

   Earnings and update

   24h Move

   -0.5%

   Released Q4 and full-year 2025 results and pipeline progress update.

3. Feb 26

   Earnings date notice

   24h Move

   +1.1%

   Announced date and time for Q4 and full-year 2025 results call.

4. Feb 25

   Investor conferences

   24h Move

   +2.1%

   Detailed participation in multiple March 2026 healthcare conferences.

5. Feb 06

   Inducement option grants

   24h Move

   +5.8%

   Disclosed inducement stock options for new employees totaling 69,750 shares.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

farnesyl transferase inhibitor, vegfr tki therapy, clear cell renal cell carcinoma, ccrcc, +3 more

7 terms

farnesyl transferase inhibitor medical

"Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib"

A farnesyl transferase inhibitor is a drug that blocks an enzyme cells use to attach certain proteins to their membranes, a step many cancer cells need to grow and survive. Think of it as removing the Velcro that lets a key worker stick to the job site; without that attachment, harmful cells can lose function or die. Investors watch these drugs because clinical trial results, regulatory decisions, or safety findings can strongly affect a biotech company's value and future revenues.

vegfr tki therapy medical

"support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy"

A VEGFR TKI therapy is a type of cancer drug that blocks signals a tumor uses to build blood vessels, cutting off the tumor’s supply lines much like turning off irrigation to weeds. Investors care because these medicines can be large, long-term revenue drivers if proven safe and effective, but they also face clinical trial, safety and competitive risks that directly affect a drug maker’s valuation and future earnings.

clear cell renal cell carcinoma medical

"in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium"

A type of kidney cancer that starts in the tubes of the kidney and is identified by tumor cells that appear clear under a microscope. Think of it as a distinct “breed” of kidney cancer with its own behavior and treatment options; that matters to investors because diagnosis rates, clinical trial outcomes, drug approvals, and treatment costs directly affect the market size and revenue prospects for companies developing therapies or diagnostics.

ccrcc medical

"cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo"

Clear cell renal cell carcinoma is the most common form of kidney cancer, named for the pale-looking cells seen under a microscope; it starts in the filtering units of the kidney and can spread to other organs. Investors watch it because the disease defines a specific market for diagnostics, drugs and clinical trials—like a product category in tech—and trial results, approvals or safety issues can materially affect companies developing treatments and their valuations.

phase 1 medical

"Preliminary Phase 1 results from FIT-001Abstract Session: 7Date: April 17, 2026"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

vegfr medical

"resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026"

VEGFR is a protein on the surface of cells that acts like a doorbell for signals that tell the body to grow new blood vessels. Investors care because therapies or tests that block or measure VEGFR can slow blood-vessel growth in tumors or abnormal eye conditions, affecting the potential value of drugs, diagnostics, and related companies; think of it as a light switch that controls a supply line to tissues, and changing it can change a company’s market prospects.

tki medical

"resensitize tumors to VEGFR TKI therapy Virtual investor call on April 17, 2026"

A TKI (tyrosine kinase inhibitor) is a type of drug that blocks specific enzymes cells use to send growth signals, effectively slowing or stopping the proliferation of certain cancer and disease cells. For investors, TKIs matter because they are often central to a biotech company's product pipeline and revenue potential: successful TKIs can win regulatory approval, command premium pricing, and shift competitive dynamics in treatment markets, much like a key component that can make or break a new technology's commercial success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Data build on findings presented at ESMO 2025 and support potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy

Virtual investor call on April 17, 2026, at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST

SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced it will present updated data from its ongoing FIT-001 clinical trial (NCT 06026410) evaluating darlifarnib (KO-2806) in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma at the International Kidney Cancer Symposium (IKCS) Europe 2026 in Paris, France.

The data to be presented build on earlier findings from the FIT-001 study reported at the 2025 European Society for Medical Oncology (ESMO) Congress, where the combination of darlifarnib and cabozantinib demonstrated encouraging clinical activity and a manageable safety profile in patients with advanced renal cell carcinoma.

IKCS Europe 2026 Presentation Details

Title: Farnesyl transferase inhibitor (FTI) darlifarnib (KO-2806) combined with cabozantinib (cabo) in clear cell renal cell carcinoma (ccRCC) patients after prior exposure to cabo: Preliminary Phase 1 results from FIT-001

Abstract Session: 7
Date: April 17, 2026
Time: 3:30 p.m. – 4:30 p.m. CEST

Virtual Investor Event
Kura will host a webcast and conference call on April 17, 2026, at 7:30 am PT / 10:30 am ET / 4:30 pm CEST featuring management and a clinical investigator from the darlifarnib program. The live webcast and replay will be available on the Company’s website at www.kuraoncology.com under the Investors tab in the Events and Presentations section.  

About darlifarnib
Darlifarnib is a next-generation farnesyl transferase inhibitor (FTI) designed to inhibit farnesylation of RHEB and suppress mTORC1 signaling. This mechanism has potential to enhance the activity of multiple targeted therapies, including VEGFR-targeted therapies such as cabozantinib.

About Kura Oncology
Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates is designed to target cancer signaling pathways and address high-need hematologic malignancies and solid tumors. Kura developed and is commercializing KOMZIFTI™ (ziftomenib), the FDA-approved once-daily, oral menin inhibitor for the treatment of adults with relapsed or refractory NPM1-mutated acute myeloid leukemia, and continues to pioneer advancements in menin inhibition and farnesyl transferase inhibition. For additional information, please visit the Kura website at https://kuraoncology.com/ and follow us on X and LinkedIn.

Forward-Looking Statements 
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include, among other things, statements regarding Kura’s presentation of FIT-001 data at IKCS Europe 2026, the therapeutic potential of the combination of darlifarnib and cabozantinib in patients with clear cell renal cell carcinoma, and the potential of darlifarnib to overcome resistance and resensitize tumors to VEGFR TKI therapy and to enhance the activity of multiple targeted therapies. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Kura faces, please refer to Kura’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. 

Kura Contact
Investors and Media:
Greg Mann
858-987-4046
gmann@kuraoncology.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will KURA present about darlifarnib plus cabozantinib at IKCS Europe 2026?

KURA will present updated Phase 1 FIT-001 data on April 17, 2026 showing encouraging activity and manageable safety. According to Kura Oncology, the data build on ESMO 2025 findings and focus on patients with prior cabozantinib exposure.

When is the KURA virtual investor event for the FIT-001 update (KURA)?

The virtual investor webcast is on April 17, 2026 at 7:30 a.m. PT / 10:30 a.m. ET / 4:30 p.m. CEST. According to Kura Oncology, management and a clinical investigator will participate and a replay will be available online.

What patient population does the FIT-001 KURA abstract address at IKCS Europe 2026?

The abstract covers clear cell renal cell carcinoma patients previously treated with cabozantinib. According to Kura Oncology, the presentation reports preliminary Phase 1 results for the darlifarnib plus cabozantinib combination in that cohort.

How do the FIT-001 results presented by KURA relate to earlier ESMO 2025 data?

The IKCS Europe update builds on ESMO 2025 findings showing encouraging clinical activity and manageable safety. According to Kura Oncology, the new data expand and update the earlier FIT-001 clinical observations.

Where can investors watch KURA's FIT-001 presentation and replay?

Investors can access the live webcast and replay on Kura Oncology's investor website under Events and Presentations. According to Kura Oncology, the webcast link and replay will be posted on the company's site after the April 17, 2026 event.